yttrium radioisotopes has been researched along with Hematologic Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Emami, Z; Khamseh, ME; Maghsoomi, Z; Malboosbaf, R; Malek, M | 1 |
| Calabrese, L; Crosta, C; Grana, C; Martinelli, G; Paganelli, G; Pinto, A; Pruneri, G; Radice, D; Rizzo, S; Vanazzi, A | 1 |
| Berkova, Z; Braun, FK; Fanale, MA; Feng, L; Fowler, N; Kwak, LW; Mathur, R; McLaughlin, P; Neelapu, SS; Pro, B; Romaguera, JE; Samaniego, F; Sehgal, L; Selvaraj, V; Shah, JJ | 1 |
| Bethge, WA; Bornhaeuser, M; Bunjes, D; Dittmann, H; Faul, C; Federmann, B; Kanz, L; Knop, S; Lange, T; Meisner, C; Stadler, M; Stelljes, M; Trenschel, R; Uharek, L; Vogel, W; von Harsdorf, S; Vucinic, V; Wulf, G | 1 |
| Baechler, S; Bochud, FO; Hobbs, RF; Jacene, HA; Sgouros, G; Wahl, RL | 1 |
| Giza, A; Hubalewska-Dydejczyk, A; Jakóbczyk, M; Jurczak, W; Skotnicki, AB; Sobociński, M; Staszczak, AS; Szostek, M; Zimowska-Curyło, D | 1 |
| Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T | 1 |
| Allegra, C; Brechbiel, M; Carrasquillo, JA; Gansow, O; Hamilton, M; Pai-Scherf, LH; Paik, C; Pastan, I; Pearson, D; Webber, K; Whatley, M; Willingham, MC | 1 |
| Germack, MA; Herpst, JM; Klein, JL; Leichner, PK; Loudenslager, DM; Order, SE; Vriesendorp, HM | 1 |
1 review(s) available for yttrium radioisotopes and Hematologic Diseases
| Article | Year |
|---|---|
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Topics: Carcinoma, Neuroendocrine; Hematologic Diseases; Humans; Iodine Radioisotopes; Octreotide; Organometallic Compounds; Radiation Injuries; Radiation Tolerance; Radiopharmaceuticals; Renal Insufficiency; Thyroid Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2021 |
6 trial(s) available for yttrium radioisotopes and Hematologic Diseases
| Article | Year |
|---|---|
Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2014 |
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Radiation Injuries; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
Topics: Adult; Aged; Antibodies, Monoclonal; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Yttrium Radioisotopes | 2010 |
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2005 |
Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Area Under Curve; Female; Hematologic Diseases; Humans; Indium Radioisotopes; Lewis Blood Group Antigens; Male; Metabolic Clearance Rate; Mice; Middle Aged; Neoplasms; Radionuclide Imaging; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2000 |
Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Combined Modality Therapy; Drug Evaluation; Female; Ferritins; Follow-Up Studies; Hematologic Diseases; Hodgkin Disease; Humans; Indium Radioisotopes; Male; Middle Aged; Radiotherapy Dosage; Survival Rate; Yttrium Radioisotopes | 1991 |
2 other study(ies) available for yttrium radioisotopes and Hematologic Diseases
| Article | Year |
|---|---|
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Bone Marrow; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Leukocyte Count; Linear Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Models, Statistical; Neutrophils; Platelet Count; Predictive Value of Tests; Radioimmunotherapy; Radiometry; Radiopharmaceuticals; Thrombocytopenia; Yttrium Radioisotopes | 2010 |
[Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab].
Topics: Antibodies, Monoclonal; Hematologic Diseases; Humans; Lymphoma, B-Cell; Radioimmunotherapy; Yttrium Radioisotopes | 2012 |